Janssen Showcases Commitment to Advancing Scientific Innovation in Pulmonary Arterial Hypertension (PAH) at CHEST 2021 Annual Meeting
TITUSVILLE, N.J. – October 14, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today 11* abstracts highlighting data from its pulmonary hypertension (PH) portfolio will be presented at CHEST 2021, the annual meeting of the American College of Chest Physicians, held virtually October 17-20.Data presentations from eight abstracts will provide additional evidence supporting the role of objective multiparameter risk assessment approaches in helping to optimize treatment and care for pulmonary arterial hypertension (PAH), as well as the impact of earlier and comprehensive therapy with ...
Source: Johnson and Johnson - October 14, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Submits Application Seeking U.S. FDA Approval of STELARA ® (ustekinumab) for the Treatment of Pediatric Patients With Juvenile Psoriatic Arthritis
HORSHAM, PENNSYLVANIA, October 8, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking expanded approval of STELARA® (ustekinumab) to treat pediatric patients ages 5 years and older with juvenile psoriatic arthritis (jPsA).The filing is supported by extrapolation of data from nine studies across both adult trials in active PsA and adult and pediatric studies in moderate to severe plaque psoriasis, totaling 3,997 patients evaluated across these closely associa...
Source: Johnson and Johnson - October 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

New Analysis Presented by Janssen at United European Gastroenterology Week (UEGW) Demonstrates Long-Term Safety Profile for STELARA ® (ustekinumab) in Older Patients Across Approved Indications
SPRING HOUSE, PENNSYLVANIA, October 4, 2021 – Today, the Janssen Pharmaceutical Companies of Johnson & Johnson announced a new analysis of STELARA® (ustekinumab) pooled safety data from 13 clinical studies across approved indications, showing rates of key safety events among adults 60 years and older treated with STELARA for up to five yearsa were similar to rates observed with placebo during the control phase of these trials.1,b Approved indications included adults with moderately to severely active Crohn’s disease (CD), moderately to severely active ulcerative colitis (UC), moderate to severe plaque p...
Source: Johnson and Johnson - October 4, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Announces Phase 2b Data Demonstrating its Investigational RSV Adult Vaccine Provided 80% Protection against Lower Respiratory Infections in Older Adults
RARITAN, N.J., October 2, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that its investigational respiratory syncytial virus (RSV) vaccine candidate was highly effective in protecting against lower respiratory tract disease (LRTD) caused by RSV, demonstrating vaccine efficacy of 80 percent (CI, 52.2-92.9%) in adults aged 65 and older. The study results were presented as a late-breaking abstract at the virtual IDWeek 2021 conference on October 2.“The findings from our CYPRESS study are very encouraging as we seek to deliver a long-awaited preventive vaccine to stave off the...
Source: Johnson and Johnson - October 2, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Announces Start of Phase 3 Trial for Investigational Respiratory Syncytial Virus (RSV) Vaccine in Older Adults
RARITAN, N.J., September 29, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the initiation of its Phase 3 EVERGREEN study. The study will evaluate the efficacy, safety and immunogenicity of Janssen’s investigational adult vaccine against lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV), when compared with placebo in approximately 23,000 adults aged 60 years and older throughout North America and a selection of countries across Europe, Asia and the Southern Hemisphere.The EVERGREEN study was initiated based on positive results from the Phase...
Source: Johnson and Johnson - September 29, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Mayo Clinic Minute: Chronic obstructive pulmonary disease brought on by tobacco
Chronic obstructive pulmonary disease (COPD) refers to a progressive group of lung diseases, including chronic bronchitis and emphysema, that make it hard to breathe. Millions of people around the globe die each year because of COPD, and nearly 16 million people in the U.S. have a form of the disease. The No. 1 cause of COPD in developed countries is tobacco smoking, according to Dr. John Costello, consultant pulmonologist at Mayo Clinic Healthcare in London. Watch:… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - September 16, 2021 Category: Databases & Libraries Source Type: news

What 9/11 Survivors and First Responders Have Taught Us About Public Health in the 20 Years Since the Attacks
Dr. David Prezant was knocked fully airborne at 9:59 on the morning of Sept. 11, 2001. He didn’t see the impact coming, but he felt it when it hit—and it nearly killed him. Little more than an hour earlier, Prezant, then the deputy chief medical officer of the Fire Department of New York, was headed for his usual workplace at the FDNY’s Office of Medical Affairs, just across the Manhattan Bridge in Brooklyn. He had already heard that a plane had hit the North Tower of the World Trade Center, and he reckoned that it was an accident. By the time he reached his office, however, the South Tower had been struc...
Source: TIME: Health - September 10, 2021 Category: Consumer Health News Authors: Jeffrey Kluger and Tara Law Tags: Uncategorized healthscienceclimate Source Type: news

Data from Multiple Studies Show Positive Outcomes with Gala Therapeutics' RheOx(TM) System for Chronic Bronchitis
SAN CARLOS, Calif., Aug. 31, 2021 -- (Healthcare Sales & Marketing Network) -- Gala Therapeutics, Inc. (Gala), a developer of medical devices to treat pulmonary disease, today announced new data from multiple clinical studies that demonstrate improvements... Devices Gala Therapeutics, RheOx, Bronchial Rheoplasty, chronic bronchitis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 31, 2021 Category: Pharmaceuticals Source Type: news

Bronchitis the Leader at Putting Children in the Hospital Bronchitis the Leader at Putting Children in the Hospital
More children admitted to hospitals in 2018 had acute bronchitis than any other disorder, according to a report from the Agency for Healthcare Research and Quality.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 3, 2021 Category: Consumer Health News Tags: Pediatrics News Source Type: news

Non-Covid respiratory illnesses on rise in UK, medical experts say
Increase in cases of bronchitis and common colds attributed to people mixing after easing of lockdownCoronavirus – latest updatesSee all our coronavirus coverageNon-Covid respiratory illnesses and other conditions that were suppressed over the winter by lockdown are slowly “marching upwards” again, albeit at a level below what doctors expect for this time of year.The increase in conditions such as bronchitis and the common cold was attributed by an expert at the Royal College of General Practitioners (RCGP) to the onset of people mixing again amid the lifting of lockdown measures.Continue reading... (Sour...
Source: Guardian Unlimited Science - July 9, 2021 Category: Science Authors: Ben Quinn Tags: Infectious diseases Coronavirus Health Medical research UK news Hospitals England Source Type: news

Health Highlights: June 25, 2021
Here's HealthDay's top stories for Friday, June 25: Colds make a comeback. As rules on mask-wearing, social distancing and mass gatherings relax, there's a surge in colds, bronchitis and other respiratory ills in doctor's offices& ERs across... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 25, 2021 Category: General Medicine Source Type: news

Colds, Bronchitis Cases Resurged After Texas Eased COVID Rules
(Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - June 9, 2021 Category: Respiratory Medicine Tags: Infections, Pulmonology, Preventive Medicine, News, Source Type: news

Colds, Bronchitis Cases Resurged After Texas Eased COVID Rules
WEDNESDAY, June 9, 2021 -- After Texas relaxed COVID-19 restrictions, other respiratory illnesses -- such as colds, bronchitis and pneumonia -- made rapid rebounds. Pathologists from Houston Methodist Hospital found that the rhinovirus and... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 9, 2021 Category: General Medicine Source Type: news

Colds, Bronchitis Cases Resurged After Texas Eased COVID Rules
Title: Colds, Bronchitis Cases Resurged After Texas Eased COVID RulesCategory: Health NewsCreated: 6/9/2021 12:00:00 AMLast Editorial Review: 6/9/2021 12:00:00 AM (Source: MedicineNet Lungs General)
Source: MedicineNet Lungs General - June 9, 2021 Category: Respiratory Medicine Source Type: news

New Phase 3b Psoriatic Arthritis (PsA) Data Show First-in-Class TREMFYA ® (guselkumab) Achieved Robust Joint Symptom Improvement and Complete Skin Clearance in Patients with Inadequate Response to Tumor Necrosis Factor Inhibition (TNFi-IR)
SPRING HOUSE, PENNSYLVANIA, June 2, 2021 – Today the Janssen Pharmaceutical Companies of Johnson & Johnson announced new efficacy and safety data for first-in-class TREMFYA® (guselkumab), including data from the first study evaluating a selective IL-23 inhibitor in adult patients with active PsA, all of whom had demonstrated inadequate response or intolerance to TNFi.1 In the COSMOS Phase 3b study, significantly higher proportions of patients treated with TREMFYA showed joint symptom improvement and complete skin clearance versus placebo at week 24 in this true TNFi-IRa patient population, which is often more...
Source: Johnson and Johnson - June 2, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Acute Bronchitis
Title: Acute BronchitisCategory: Diseases and ConditionsCreated: 9/2/2005 12:00:00 AMLast Editorial Review: 5/25/2021 12:00:00 AM (Source: MedicineNet Lungs General)
Source: MedicineNet Lungs General - May 25, 2021 Category: Respiratory Medicine Source Type: news

Gala Therapeutics Announces First Patients Enrolled in Pivotal Trial of RheOx(TM) System for Chronic Bronchitis
SAN CARLOS, Calif., May 20, 2021 -- (Healthcare Sales & Marketing Network) -- Gala Therapeutics, Inc. (Gala), a developer of medical devices to treat pulmonary disease, has initiated its pivotal clinical trial to evaluate its RheOx™ Bronchial Rheoplasty S... Devices Gala Therapeutics, RheOx, Bronchial Rheoplasty, bronchitis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 20, 2021 Category: Pharmaceuticals Source Type: news

New Phase 3 Data Showed First-in-Class TREMFYA ® (guselkumab) Provided Durable Complete Skin Clearance Through Five Years in Moderate to Severe Plaque Psoriasis (PsO) and Robust Joint Symptom Improvement Through 52 Weeks in Active Psoriatic Arthritis (PsA)
SPRING HOUSE, PENNSYLVANIA, April 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new Phase 3 data which showed TREMFYA® (guselkumab) sustained durable, complete skin clearance rates in a majority of adults with moderate to severe plaque psoriasis (PsO) through five years (252 weeks), a and improved disease activity and axial symptoms in adults with active psoriatic arthritis (PsA) through one year (52 weeks).1,2,3 These data are being presented at the American Academy of Dermatology Virtual Meeting Experience 2021, where Janssen will present a total of 22 abstracts. TREMF...
Source: Johnson and Johnson - April 23, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

ACP Offers Guidance on Antibiotic Duration for Common Infections
Best practices recommend limiting antibiotics to five days for COPD exacerbations, acute uncomplicated bronchitis (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - April 21, 2021 Category: Respiratory Medicine Tags: Dermatology, Family Medicine, Gastroenterology, Gynecology, Infections, Internal Medicine, Emergency Medicine, Ophthalmology, ENT, Pharmacy, Pulmonology, Urology, Journal, Source Type: news

New Phase 3 Data Show First-in-Class TREMFYA ® (guselkumab) Achieved Complete Skin Clearance and Favorable Joint Efficacy in Adult Patients with Active Psoriatic Arthritis (PsA) Through Two Years
SPRING HOUSE, PENNSYLVANIA, March 16, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced long-term data from the Phase 3 DISCOVER-2a study showing that the skin clearance, joint symptom relief, and safety of TREMFYA® (guselkumab) previously demonstrated through 24 weeks and one year (Week 52) in adults with active psoriatic arthritis (PsA) continued through two years (Week 112).1,2 These findings also confirmed that the robust efficacy TREMFYA demonstrated in patients at Week 24 on physical function, physical aspects of health-related quality of life, and resolution of enthesitis...
Source: Johnson and Johnson - March 16, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Lung cancer symptoms: Bronchitis that won't go away is an early warning sign
LUNG cancer is one of the most common and serious types of cancer, with around 47,000 people diagnosed with the condition every year in the UK. Bronchitis that doesn't go away is an early warning sign. (Source: Daily Express - Health)
Source: Daily Express - Health - February 23, 2021 Category: Consumer Health News Source Type: news

How Do You Know if You Have Bronchitis or COVID-19 (Coronavirus)?
Title: How Do You Know if You Have Bronchitis or COVID-19 (Coronavirus)?Category: Diseases and ConditionsCreated: 2/17/2021 12:00:00 AMLast Editorial Review: 2/17/2021 12:00:00 AM (Source: MedicineNet Lungs General)
Source: MedicineNet Lungs General - February 17, 2021 Category: Respiratory Medicine Source Type: news

What Is the Best Medicine and Treatment for Bronchitis?
Title: What Is the Best Medicine and Treatment for Bronchitis?Category: Diseases and ConditionsCreated: 2/16/2021 12:00:00 AMLast Editorial Review: 2/16/2021 12:00:00 AM (Source: MedicineNet Lungs General)
Source: MedicineNet Lungs General - February 16, 2021 Category: Respiratory Medicine Source Type: news

Acute Bronchitis Contagoius Symptoms, Causes, Treatment, and Recovery Time
Title: Acute Bronchitis Contagoius Symptoms, Causes, Treatment, and Recovery TimeCategory: Diseases and ConditionsCreated: 9/2/2005 12:00:00 AMLast Editorial Review: 2/9/2021 12:00:00 AM (Source: MedicineNet Lungs General)
Source: MedicineNet Lungs General - February 9, 2021 Category: Respiratory Medicine Source Type: news

How Do You Know If Your Child Has Bronchitis?
Title: How Do You Know If Your Child Has Bronchitis?Category: Diseases and ConditionsCreated: 1/21/2021 12:00:00 AMLast Editorial Review: 1/21/2021 12:00:00 AM (Source: MedicineNet Lungs General)
Source: MedicineNet Lungs General - January 21, 2021 Category: Respiratory Medicine Source Type: news

Is Bronchitis Contagious Through Kissing?
Title: Is Bronchitis Contagious Through Kissing?Category: Diseases and ConditionsCreated: 1/8/2021 12:00:00 AMLast Editorial Review: 1/8/2021 12:00:00 AM (Source: MedicineNet Lungs General)
Source: MedicineNet Lungs General - January 8, 2021 Category: Respiratory Medicine Source Type: news

What Is the Treatment for Asthmatic Bronchitis?
Title: What Is the Treatment for Asthmatic Bronchitis?Category: Diseases and ConditionsCreated: 12/21/2020 12:00:00 AMLast Editorial Review: 12/21/2020 12:00:00 AM (Source: MedicineNet Asthma General)
Source: MedicineNet Asthma General - December 21, 2020 Category: Respiratory Medicine Source Type: news

How Do You Know if Your Baby has Bronchitis?
Title: How Do You Know if Your Baby has Bronchitis?Category: Diseases and ConditionsCreated: 12/16/2020 12:00:00 AMLast Editorial Review: 12/16/2020 12:00:00 AM (Source: MedicineNet Lungs General)
Source: MedicineNet Lungs General - December 16, 2020 Category: Respiratory Medicine Source Type: news

What Are the Main Causes of Bronchitis?
Title: What Are the Main Causes of Bronchitis?Category: Diseases and ConditionsCreated: 12/15/2020 12:00:00 AMLast Editorial Review: 12/15/2020 12:00:00 AM (Source: MedicineNet Lungs General)
Source: MedicineNet Lungs General - December 15, 2020 Category: Respiratory Medicine Source Type: news

Roche announces FDA approval of Xofluza for the prevention of influenza following contact with an infected person
             Basel, 24 November 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Xofluza ® (baloxavir marboxil) as a treatment to prevent influenza in people 12 years of age and older following contact with someone with influenza (known as post-exposure prophylaxis). Xofluza is the first single-dose influenza medicine approved for post-exposure prophylaxis.“With today’s approval, Xofluza is now available as the first single-dos...
Source: Roche Investor Update - November 24, 2020 Category: Pharmaceuticals Source Type: news

Roche announces FDA approval of Xofluza for the prevention of influenza following contact with an infected person
             Basel, 24 November 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Xofluza ® (baloxavir marboxil) as a treatment to prevent influenza in people 12 years of age and older following contact with someone with influenza (known as post-exposure prophylaxis). Xofluza is the first single-dose influenza medicine approved for post-exposure prophylaxis.“With today’s approval, Xofluza is now available as the first single-dos...
Source: Roche Media News - November 24, 2020 Category: Pharmaceuticals Source Type: news

E-cigarette users have 30% higher risk for chronic lung diseases, study finds
E-cigarette users have a roughly 30% higher risk for developing respiratory illness, such as chronic obstructive pulmonary disease, emphysema, chronic bronchitis and asthma than non-users, according to a study in JAMA. (Source: Health News - UPI.com)
Source: Health News - UPI.com - November 12, 2020 Category: Consumer Health News Source Type: news

CSA Medical Announces Enrollment Milestone in a Mechanism of Action Study utilizing the RejuvenAir(R) System for COPD Patients with Chronic Bronchitis
This study will provide a scientific rationale for the remodeling response and clinical improvements identified in the feasibility study BOSTON, Nov. 11, 2020 -- (Healthcare Sales & Marketing Network) -- CSA Medical, Inc., today announced that over hal... Devices CSA Medical, cryotherapy, RejuvenAir, COPD, Bronchitis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 11, 2020 Category: Pharmaceuticals Source Type: news

New source of lymphatic system leak discovered in children with rare open heart surgery complication
(Nemours) Interventional radiologists with Nemours Children's Health System have identified a new source of abnormal lymphatic flow between the liver and the lungs that may be responsible for some cases of plastic bronchitis. Plastic bronchitis is a rare but serious late complication in patients with congenital heart disease who had Fontan surgery. A report detailing the discovery of this fluid leak, and successful treatment of two cases was published in European Heart Journal. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 11, 2020 Category: International Medicine & Public Health Source Type: news

CSA Medical Announces First Procedure in the SPRAY-CB Pivotal Trial for the Treatment of Chronic Bronchitis
The SPRAY-CB trial marks the first pivotal study of a medical device therapy targeting the underlying cause of Chronic Bronchitis BOSTON, Oct. 22, 2020 -- (Healthcare Sales & Marketing Network) -- CSA Medical Inc., a developer of medical devices advanc... Devices CSA Medical, cryotherapy, RejuvenAir System, COPD (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 22, 2020 Category: Pharmaceuticals Source Type: news

Temple treats 1st patient in trial of RejuvenAir Metered Cryospray System for COPD with CB
(Temple University Health System) Temple University Hospital has treated the first patient in a multicenter international clinical trial utilizing the RejuvenAir ® System for the treatment of patients suffering from moderate to severe COPD with chronic bronchitis. Chronic bronchitis is characterized by a productive cough for months or years. Dr. Gerard Criner, Chair and Professor of Thoracic Medicine and Surgery at the Lewis Katz School of Medicine and Director of the Temple Lung Center, is the overall principal investigator. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 20, 2020 Category: International Medicine & Public Health Source Type: news

Bronchitis in Early Childhood Linked to Later Lung Disease
Lung diseases occurring later in life more likely to be asthma, pneumonia rather than chronic bronchitis (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - October 2, 2020 Category: Respiratory Medicine Tags: Family Medicine, Infections, Internal Medicine, Allergy, Pediatrics, Pulmonology, Conference News, Source Type: news

Bronchitis in Early Childhood Linked to Later Lung Disease
THURSDAY, Oct. 1 2020 -- Children who have bronchitis at least once before the age of 7 years are more likely to develop lung problems in later life, according to a study presented at the European Respiratory Society International Congress 2020,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 1, 2020 Category: Pharmaceuticals Source Type: news

SIMPONI ARIA ® (golimumab) Approved by the U.S. Food and Drug Administration for Active Polyarticular Juvenile Idiopathic Arthritis and Extension of Its Active Psoriatic Arthritis Indication in Patients 2 Years of Age and Older
HORSHAM, PA, September 30, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved SIMPONI ARIA® (golimumab) for patients 2 years of age and older for the treatment of active pJIA and has extended the PsA indication for this same patient population. “This latest FDA approval of SIMPONI ARIA for pediatric use in active pJIA and active PsA not only brings a new option to young patients living with these diseases but also adds to the growing body of evidence for this treatment,” said Mathai Mammen, M.D., Ph.D., Glo...
Source: Johnson and Johnson - September 30, 2020 Category: Pharmaceuticals Source Type: news

What Helps When You Have Bronchitis?
Title: What Helps When You Have Bronchitis?Category: Diseases and ConditionsCreated: 9/29/2020 12:00:00 AMLast Editorial Review: 9/29/2020 12:00:00 AM (Source: MedicineNet Lungs General)
Source: MedicineNet Lungs General - September 29, 2020 Category: Respiratory Medicine Source Type: news

Donor-conceived adults have higher incidence of immunology diseases
(Flinders University) Adults conceived through sperm donation reported higher frequencies of allergies, type 1 diabetes and other autoimmune conditions. Donor sperm conceived adults had seven times more type 1 diabetes diagnoses; double the incidence of thyroid disease, acute bronchitis and sleep apnoea; and 10% more reported allergies. The study looked at 272 donor-conceived adult participants compared to 877 conceived naturally, from around the world with most from Australia, US, UK, Belgium and Netherlands. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - September 23, 2020 Category: Biology Source Type: news

Bronchitis in Childhood Tied to Worse Lung Health in Adulthood Bronchitis in Childhood Tied to Worse Lung Health in Adulthood
Children who suffer a bout of bronchitis at least once before their seventh birthday are at increased risk for developing lung problems such as asthma and pneumonia later in life, a study suggests.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - September 14, 2020 Category: Allergy & Immunology Tags: Pulmonary Medicine News Source Type: news

Bronchitis can be treated with a 'flash-freeze' icy blast to the lungs in new 30 minute procedure
The RejuvenAir procedure is being offered as part of a trial at the Royal Brompton & Harefield NHS Foundation Trust and the Chelsea & Westminster Hospital NHS Foundation Trust. (Source: the Mail online | Health)
Source: the Mail online | Health - August 15, 2020 Category: Consumer Health News Source Type: news

Covid lockdown: England sees fewer cases of colds, flu, and bronchitis, BMJ
Figures published by the Royal College of General Practitioners, derived from data from 500 practices across England, suggest that lockdown and physical distancing measures to prevent the spread of covid-19 were the probable cause of the trend. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - August 13, 2020 Category: Consumer Health News Source Type: news

Cold, flu and bronchitis infections fell 'well below average' during coronavirus lockdown
A report by the Royal College of GPs shows rates for these viruses fell drastically when the UK locked down in late March. Ten times fewer were going to their GP with a cold last month. (Source: the Mail online | Health)
Source: the Mail online | Health - August 10, 2020 Category: Consumer Health News Source Type: news

TREMFYA ® (guselkumab) Approved by U.S. Food and Drug Administration as the First Selective Interleukin (IL)-23 Inhibitor for Active Psoriatic Arthritis
HORSHAM, PA, July 14, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved TREMFYA® (guselkumab) for adult patients with active psoriatic arthritis (PsA), a chronic progressive disease characterized by painful joints and skin inflammation.[1],[2] TREMFYA is the first treatment approved for active PsA that selectively inhibits interleukin (IL)-23, a naturally occurring cytokine that is involved in normal inflammatory and immune responses associated with the symptoms of PsA. The safety and efficacy of TREMFYA in PsA have b...
Source: Johnson and Johnson - July 14, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Follow-up appointments for children hospitalized for bronchiolitis may not be needed
(Intermountain Medical Center) A new study at Intermountain Primary Children's Hospital in Salt Lake City has found that follow-up appointments for hospitalized children treated for childhood bronchitis are often not necessary, and that switching from mandatory to 'as-needed' follow-up care can save families from unnecessary medical care and expense - and may help guide treatment during the COVID-19 pandemic. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - July 6, 2020 Category: International Medicine & Public Health Source Type: news

Children ’ s Robitussin And Dimetapp Cough Medicines Recalled For Potential Overdose Risks
(CNN) — Parents take note: GlaxoSmithKline Consumer Healthcare has voluntarily recalled three lots of its children’s cough syrups — Children’s Robitussin Honey Cough and Chest Congestion DM and Children’s Dimetapp Cold and Cough — due to the products having incorrect dosing cups in their packaging. That means parents might accidentally overdose a child by putting too much syrup in the cup. Symptoms of overdose of either product may include impaired coordination, elevated blood pressure, dizziness, seizure, nausea, vomiting, constipation, diarrhea, abdominal pain, hallucinations, among ot...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - June 19, 2020 Category: Consumer Health News Authors: Health – CBS Boston Tags: Consumer Health News CNN Cough Syrup Recall Source Type: news

Subcutaneous Daratumumab Combination Resulted in Deep and Rapid Hematologic Responses and Improved Clinical Outcomes in the Treatment of Patients with Newly Diagnosed Light Chain (AL) Amyloidosis
RARITAN, NJ, June 13, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the first randomized Phase 3 study investigating subcutaneous daratumumab[i] in the treatment of patients with newly diagnosed light chain (AL) amyloidosis, a rare and potentially fatal disease.[1],[2] The data demonstrated subcutaneous daratumumab in combination with cyclophosphamide, bortezomib, and dexamethasone (D-CyBorD) resulted in a higher hematologic complete response rate (CR), (53 percent vs. 18 percent [P
Source: Johnson and Johnson - June 15, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Inherent Flaws in COVID-19 Testing Mean Some of Those Infected Don ’t Get the Treatment They Need
In late February, several weeks before the coronavirus outbreak shut down American cities and rose to the level of a national crisis, Kerri Rawson began to feel sick. “I was hit out of nowhere with what feels like the flu at first,” says Rawson, who also has asthma and takes cardiac medication for high-blood pressure. “You’re fine, and then all of a sudden you have a fever below 100°F and chest congestion.” Rawson is a 41-year-old writer and mother of two in Florida. (You may recognize her name from her 2019 memoir, about growing up as the daughter of a serial killer.) Her fever lasted for...
Source: TIME: Health - May 8, 2020 Category: Consumer Health News Authors: Zach Schonfeld Tags: Uncategorized COVID-19 feature Source Type: news